Enovis (ENOV) closed at $27.16 on November 6, 2026, down 5.1% from the previous close, on volume of 1,704,912 shares (30-day average 1,634,171).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 4, 2026 | Call Spread | 20-Nov-2622.5 : 25 C | 5,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Enovis (ENOV) Gets a Buy from Canaccord Genuity
TipRanks (Fri, 6-Nov 9:23 AM ET)
Enovis (ENOV) Receives a Buy from Wells Fargo
TipRanks (Fri, 6-Nov 9:16 AM ET)
Enovis: Improved Outlook and Growth Drivers Support Buy Rating as Price Target Rises to $42
TipRanks (Fri, 6-Nov 9:08 AM ET)
Enovis raises 2026 profit guidance as Reconstructive segment posts 6% organic sales growth
Market Chameleon (Thu, 5-Nov 6:52 AM ET)
At a glance: stocks gapping up premarket
Seeking Alpha News (Thu, 5-Nov 7:25 AM ET)
Enovis Corporation Non-GAAP EPS of $0.88 beats by $0.11, revenue of $558.7M beats by $1.55M
Seeking Alpha News (Thu, 5-Nov 6:22 AM ET)
ENOVIS Announces Third Quarter 2026 Results
Globe Newswire (Thu, 5-Nov 6:00 AM ET)
Enovis Corporation Q3 2026 Earnings Preview
Seeking Alpha News (Wed, 4-Nov 1:11 PM ET)
Globe Newswire (Thu, 22-Oct 12:17 PM ET)
Enovis to Host Third Quarter 2026 Results Conference Call on November 5th
Globe Newswire (Thu, 8-Oct 8:00 AM ET)
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.
Enovis trades on the NYSE stock market under the symbol ENOV.
As of November 6, 2026, ENOV stock price declined to $27.16 with 1,704,912 million shares trading.
ENOV has a beta of 0.25, meaning it tends to be less sensitive to market movements. ENOV has a correlation of 0.00 to the broad based SPY ETF.
ENOV has a market cap of $1.57 billion. This is considered a Small Cap stock.
Last quarter Enovis reported $559 million in Revenue and $.88 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.14.
In the last 3 years, ENOV traded as high as $65.03 and as low as $16.70.
The top ETF exchange traded funds that ENOV belongs to (by Net Assets): IJR, AVUV, IWM, VTI, DFSV.
ENOV has underperformed the market in the last year with a return of -4.4%, while SPY returned +10.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ENOV shares. However, ENOV has outperformed the market in the last 3 month and 2 week periods, returning +3.2% and +28.8%, while SPY returned -4.1% and -3.2%, respectively. This indicates ENOV has been having a stronger performance recently.
ENOV support price is $27.38 and resistance is $29.86 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ENOV shares will trade within this expected range on the day.
